U.S. Drug Overdose Deaths Resurge to Record During the Pandemic

Home - toxicology

U.S. Drug Overdose Deaths Resurge to Record During the Pandemic

News       About Us        Randox Toxicology

22 October 2020: U.S. Drug Overdose Deaths Resurge to Record During the Pandemic

Drug overdose deaths in the USA rose to a record high in 2019, after falling for the first time for 25 years in 2018. Almost 72,000 people died from drug overdoses in 2019 according to the preliminary data that was released by the Centres for Disease Control and Prevention earlier this year.

Though there is currently no hard data available, there is speculation that the pandemic is complicating and worsening the surge, as 2020 looks to be even more devastating than 2019. Data collected by The New York Times saw for the first half of 2020 drug overdose deaths have risen by an average of 13 percent across America compared to last year. If this trend continues into the rest of the year, it will be the sharpest rise in annual drug deaths since 2016, when fentanyl made its way into US drug trafficking and street supply.

Increased funding toward addiction treatment, prevision and recovery services did shows signs of improving overdose deaths. Though the government has made this positive headway in the last few years in how they tackle the drug epidemic in America, this progress could be threatened by the current COVID-19 pandemic.

Earlier in the month, Brett Giroir, the administration’s assistant secretary for health, said in a statement, “We understand that there is an extraordinary amount of work to do, especially now as we are also dealing with the Covid-19 pandemic that could markedly affect our nation’s mental health and risk of substance use.”

Several public health experts said conditions created by the pandemic could hurt the nation’s fragile progress in fighting the surge of drug deaths but noted that the overdose rate was on its way back up well before the virus arrived. “Covid just makes it a bit worse,” said Dr. Dan Ciccarone, a professor of medicine at the University of California, San Francisco, who studies the opioid epidemic. “It’s a small wave riding on top of a tsunami that continues to devastate.”

Although official statistics on 2020 overdose deaths won’t be available for a long time, there is local evidence showing drug related deaths are rising into 2020.

Increase in Drug related deaths from 2019 through the first portion of 2020

Though a lot of this data precedes the coronavirus pandemic, researchers believe there are several reasons why the virus could worsen the trend.

When state lockdowns first began in March, Dr. Anna Lembke, a clinician with Stanford’s Addiction Medicine Dual Diagnosis Clinic, noticed many of her patients showing signs of improving. “Many patients described a kind of peacefulness without the constant hubbub of modern life and the constant triggers they’re exposed to,” she said.

However, in response to the virus, the US government has done something unheard-of: it relaxed rules and regulations around prescribing methadone and buprenorphine, two commonly prescribed opioid addiction treatments. Patients no longer needed to attend daily in person appointments to receive their methadone prescriptions and could instead be given 4 weeks’ worth at a time. Doctors no longer need to meet in person to prescribe buprenorphine.

This was initially celebrated as a positive change, however as the pandemic has progressed and people have remained isolated, lockdown has become harmful to people with mental health issues and drug addiction disorders.

“Social isolation has always been a huge component of drug overdose risk,” said Traci Green, an epidemiologist at Brown University who studies drug abuse and addiction. “So much of what we’ve been trying to do has been completely unravelled.”

Experts have pointed to other dangers lockdown poses such as;

  • Lack of revival fall back from other users due to an increase in solo drug users
  • Less emotional support as in person visits are scaled back
  • Inconsistent drug strength and quality
  • Supply or income disruption leading to inconsistent drug use habits and accidental overdose

 

Randox Toxicology

Using our revolutionary Biochip Array Technology, the Evidence MultiSTAT is a fully automated benchtop analyser that enables onsite, simultaneous testing for up to 21 classical, synthetic or prescription drugs from a single sample in under 20 minutes. This quick and highly reliable technology makes it perfect for use in hospitals and medical centres, as pressure increases with the rising number of drug overdose deaths in the US.

 

To find out more about our Biochip Array Technology and our Evidence Series range of analysers, visit www.randoxtoxicology.com or email info@randoxtoxicology.com

Randox Toxicology Products and Services

BIOCHIP

EVIDENCE

ELISA

MATRICES

Want to know more about Randox?

Contact us or visit our homepage to view more.


Italian Authorities Seize Over $1B Worth of Amphetamines Originating From Syria

News       About Us        Randox Toxicology

23 September August 2020: Italian Authorities Seize Over $1B Worth of Amphetamines Originating From Syria

Italian police intercepted and seized 14 tons of amphetamines with a street value of approximately $1.15 billion at the Italian port of Salerno in early July. This huge shipment was suspected to have originated from Syria before being transported to the base of a notorious European crime organisation in Naples.

‘Largest seizure of amphetamines in the world’

In video footage the Italian Financial Guard military force posted to their Twitter account, authorities can be seen using electric saws to cut through 6-foot-high cylinders in shipping containers. The Customs Police Col. Domenico Napolitano called the discovery the largest seizure of amphetamines in the world after finding over 85 million pills inside the cylinders.

Syria Identified as One of the Largest Producers of Amphetamines in the World

Syria has become one of the world’s largest producers of amphetamines in recent years, and with production and distribution of such drugs in Europe appearing to have slowed down during the pandemic, the same cannot be said for Syria. As such, authorities are suspecting that crime organisations are placing orders and smuggling drugs from Syria into Europe.

Randox Toxicology

Randox Toxicology are helping to fight drug trafficking by continually investing in new technologies to aid in the rapid and large-scale screening for drugs of abuse. We are world leaders in drug testing solutions with the capability of detecting over 500 drug and drug metabolites using our innovative Biochip Array Technology – the most comprehensive on the drug testing market. Our patented Biochip Array Technology works across a variety of matrices including whole blood, urine and oral fluid.

Using our revolutionary Biochip Array Technology, the Evidence MultiSTAT is a fully automated benchtop analyser that enables onsite, simultaneous testing for up to 21 classical, synthetic or prescription drugs from a single sample in under 20 minutes. This quick and highly reliable technology makes it perfect for use in non-laboratory settings for people with no lab experience.

 

To find out more about our Biochip Array Technology and our Evidence Series range of analysers, visit www.randoxtoxicology.com or email info@randoxtoxicology.com

 

Randox Toxicology Products and Services

BIOCHIP

EVIDENCE

ELISA

MATRICES

Want to know more about Randox?

Contact us or visit our homepage to view more.


Rise in Lockdown Drug Use Linked to Mental Health Issues

News       About Us        Randox Toxicology

19 August 2020: Rise in Lockdown Drug Use Linked to Mental Health Issues

A new survey has been published reporting on the devastating effects that nationwide and global lockdowns have had on people suffering with mental health issues and substance abuse.

The survey delves into not only what drugs are being taken, but also crucially, why people are resorting to substance abuse during lockdown. Benzodiazepines and cannabis reportedly  ‘greatly increased’ or ‘increased’ in use within the first 4 weeks of the pandemic. Approximately one in two people surveyed are taking drugs currently; a sharp increase from one in five people before the pandemic.

 

Anxiety, loneliness and stress

The majority of respondents (71%) reported that they are still using drugs for fun, however there was also a significant rise in those reporting their reason for drug use as a way to cope with their mental health.

Mental health concerns that came up were; anxiety, loneliness, stress and escaping reality.  Previously when this survey was conducted before the pandemic, each of these elements of mental health were reported at around 20%. Now however, they are being reported in approximately 30-50% of respondents.

This is understandable, given the uncertainty of what lies ahead, and the fact that some will also be struggling with unemployment, money, relationships and self-confidence.

 

Reduced Health Care Options

Unfortunately, many health facilities have been operating at reduced capacity and have been unable to see patients due to the outbreak, meaning that people are indeed turning to drug use instead of professional medical help.

As countries begin to open back up again and resume more normal health care activities, they will almost certainly see a rise in people seeking treatment for drug use.

Using our revolutionary Biochip Array Technology, the Evidence MultiSTAT is a fully automated benchtop analyser that enables onsite, simultaneous testing for up to 21 classical, synthetic or prescription drugs from a single sample in under 20 minutes.

To find out more about our Biochip Array Technology and our Evidence Series range of analysers, please visit randoxtoxicology.com or email info@randoxtoxicology.com

 

Randox Toxicology Products and Services

BIOCHIP

EVIDENCE

ELISA

MATRICES

Want to know more about Randox?

Contact us or visit our homepage to view more.


Chicago’s Rising Fentanyl Problem: A Randox Toxicology Report

News       About Us        Randox Toxicology

Chicago’s Rising Fentanyl Problem: A Randox Toxicology Report

Abuse of opioids, and in particular, fentanyl, has been on the rise in the United States in recent years. The number of patients being prescribed painkillers has almost quadrupled since the 90s from 76 million to 289 million in 2016. It has been described as a uniquely American problem, where pain relief prescriptions are about 40% higher than other developed countries.

Inevitably due to the high addiction rate of opioids, this has unfortunately led to increasing overdose deaths. In 2017 alone over 70,000 people died from drug overdoses in the USA with opioids being involved in 67.8% of cases.

Chicago Illinois is no exception to this crisis. The National Institute of Drug Abuse found that Illinois has a rate of 17.2 deaths per 100,000 people from opioid overdoses, compared to the national average of 14.6. It is not only prescription painkillers that are adding to the opioid addiction crisis in Chicago, but substances such as fentanyl that is illegally sold on the street.

Fentanyl is a cheaper, synthetic opioid which can be 50 times more potent than heroin and 100 times more potent than morphine. It is commonly added to heroin to increase strength and cut costs. Many users believe they are purchasing heroin when in fact it can be mostly fentanyl, resulting in rising overdose deaths. The DEA’s Chicago lab have stated that the drug is making up a more of their workload than ever and becoming a regular drug they see.

Randox Toxicology

Randox Toxicology are world leaders in drug testing solutions with the capability of detecting over 500 drug and drug metabolites using our innovative Biochip Array Technology – the most comprehensive on the drug testing market. Using our revolutionary patented Biochip Array Technology, the Evidence MultiSTAT is a fully automated benchtop analyzer that enables on-site simultaneous detection of up to 21 classical, prescription and synthetic drugs of abuse from a single sample.

Designed to work across a variety of matrices including; whole blood, urine, and oral fluid our patented multi-analyte testing platform provides a complete and highly accurate toxicology profile in 17-20 minutes. Most impressively the MultiSTAT has been designed to be fully operated from sample input to results output by someone with absolutely no laboratory experience and in any environment.

To find out more about our Biochip Array Technology and our Evidence Series range of analysers, visit www.randoxtoxicology.com or email info@randoxtoxicology.com

Randox Toxicology Products and Services

BIOCHIP

EVIDENCE

ELISA

MATRICES

Want to know more about Randox?

Contact us or visit our homepage to view more.


Drug Use in Australia: A Randox Toxicology Report

News       About Us        Randox Toxicology

19 March 2020

 

 

 

Drug Use in Australia

 

 

Drug Use in Australia: A Randox Toxicology Report

Approximately 43% of all Australians aged 14 years and over have admitted to using an illicit drug on at least one occasion throughout their life.

Additionally, nearly 16% of Australians have confessed to using an illicit drug at least once in the last year.

Cannabis is the most frequent drug used among the Australian people with an estimate of 35% lifetime use. The closest to this is MDMA which has an estimate of around 11% lifetime use.

A reason towards the high cannabis use may be due to the Australian Capital Territory legalizing the recreational possession and cultivation of marijuana in September 2019. This now allows any residents of the capital territory over the age of 18 to possess up to 50 grams of dried marijuana and grow two plants per person or four per household at a time. The supply of the drug to other people however still remains an illegal act.

It is estimated that approximately 60 per cent of those who use illicit drugs are also daily smokers and/or consume alcohol at a level that is considered to be of risk to their everyday health. Another noticeable finding among drug users in Australia is that the majority of methamphetamine, cocaine or ecstasy users are also users of other illicit drugs.

Using our revolutionary Biochip Array Technology, the Evidence MultiSTAT is a fully automated benchtop analyser that enables onsite, simultaneous testing for up to 21 classical, synthetic or prescription drugs from a single sample in under 20 minutes.

To find out more about our Biochip Array Technology and our Evidence Series range of analysers, visit www.randoxtoxicology.com or email info@randoxtoxicology.com

Randox Toxicology Products and Services

BIOCHIP

EVIDENCE

ELISA

MATRICES

Want to know more about Randox?

Contact us or visit our homepage to view more.


Illicit drugs costs the USA more than $740 billion annually

News       About Us        Randox Toxicology

18 February 2020

 

 

Illicit drugs affecting the US economy

 

Illicit drugs costs the USA more than $740 billion annually

The abuse of tobacco, alcohol, and illicit drugs is extremely costly to the USA, exacting more than $740 billion annually in costs related to crime, lost work productivity and health care, according to a report by the National Institute on Drug Abuse.

A substantial number of 70,237 drug overdose deaths occurred in the United States in 2017. Opioids are currently the main driver of drug overdose deaths. Opioids were involved in some 47,600 overdose deaths in 2017 (67.8% of all drug overdose deaths).

In 2017, the states with the highest rates of death due to drug overdose were West Virginia, Ohio, Pennsylvania, the District of Columbia, and Kentucky. States with statistically significant increases in drug overdose death rates from 2016 to 2017 included Alabama, Arizona, California, Connecticut, Delaware, Florida, Georgia, Illinois, Indiana, Kentucky, Louisiana, Maine, Maryland, Michigan, New Jersey, New York, North Carolina, Ohio, Pennsylvania, South Carolina, Tennessee, West Virginia, and Wisconsin.

Randox Toxicology are first to market when it comes to testing for the latest drugs of abuse and new psychoactive substances on the market.  Our revolutionary Biochip Array Technology provides state-of-the-art drug detection, utilizing simultaneous drug detection from a single sample across multiple matrices.

To find out more join us at AAFS February 17-22, Anaheim Convention Center, booth #508. Our reps Pankaj, Khushbu and Matt will be there demonstrating our Biochip technology and our Evidence MultiSTAT.

You can also email us at: info@randoxtoxicology.com or visit our website: www.randoxtoxicology.com

Randox Toxicology Products and Services

BIOCHIP

EVIDENCE

ELISA

MATRICES

Want to know more about Randox?

Contact us or visit our homepage to view more.


The 2019 World Drug Report from Randox Toxicology

News       About Us        Randox Toxicology

24 January 2020

 

2019 World Drug Report

In the turn of the new year, Randox Toxicology have compiled a 2019 report of trends in drug abuse throughout the world and what the key figures say about drug use in the world.

Opioids

An easy way of seeing how prevalent opioid use is, is the number of opioid overdose deaths. While surveys show an overall decline in the non-medical use of opioids, opioid related deaths continue to increase. The United States recorded the highest number of opioid overdose deaths at over 28,000. Europe is not as heavily affected by opioid use, an example being Sweden. Sweden has the highest number of opioid overdose deaths in Europe, at 590.

Cocaine

Global seizures rose to 1,275 tons, the largest quantity ever reported. This figure highlights the increase in cocaine trafficking. With an estimated 4.2 million people (1.3 per cent of the population) using cocaine, usage of the drug was highest in Western and Central Europe, which accounted for some 90 per cent of all the cocaine use in Europe as a whole.

In Australia, 2.5 per cent of the population aged 14 and older were estimated to have used cocaine in the previous year. The highest estimated prevalence of cocaine was among young adults aged 20-29 also.

Cocaine use was not popular in both Africa in Asia. For Africa, the use of cocaine was estimated to be between 0.02 per cent and 0.40 per cent of the population, while in Asia the cocaine use was estimated to be between 0.04 and 0.07 per cent.

Methamphetamine

The information available globally on methamphetamine, although limited, indicates that there has been a market expansion. The data available shows that this market has been expanding and that the two largest ‘demand regions’ are South-East Asia and North America.

In terms of methamphetamine that has been seized, North American and South-East Asia, respectively account for 49 per cent and 42 per cent of global quantities seized. Despite the overall expansion of methamphetamine markets worldwide, most of the trafficking continues to be intraregional, for example, trafficking within North America or within South-East Asia.

Our testing solution

Randox Toxicology are first to market when it comes to testing for the latest drugs of abuse and new psychoactive substances in the market.  Our revolutionary Biochip Array Technology provides state-of-the-art drug detection, utilizing simultaneous drug detection from a single sample across multiple matrices.

Our ELISA kits provide a comprehensive test menu, covering a broad range of drugs of abuse, stimulants, analgesics and sedatives. Randox Toxicology develop the highest quality 96-well microtitre plates available to the market, with results providing excellent correlation with confirmatory methods.

To find out more email us at: info@randoxtoxicology.com or visit our website: www.randoxtoxicology.com

Randox Toxicology Products and Services

BIOCHIP

EVIDENCE

ELISA

MATRICES

Want to know more about Randox?

Contact us or visit our homepage to view more.


The Drug Epidemic in The Seychelles Islands

News       About Us        Randox Toxicology

24 December 2019

 

The Drug Epidemic in The Seychelles Islands

The Seychelles is suffering from a drug epidemic. Nearly 10% of its 94000 population are addicted to heroin, according to the Agency for the Prevention of Drug Abuse and Rehabilitation (APDAR) in the Seychelles.

Per capita, the Seychelles suffers from the highest rate of heroin abuse in the world. Heroin makes the long journey from Central Asia, especially Afghanistan, before being smuggled to the islands via East Africa. Made up of 115 islands, the Seychelles has many porous borders, which makes them hard to monitor and easy for the drugs to come into the country. Rather than attempting a “war on drugs”, which would criminalise the large proportion of heroin users in the Seychelles, the head of the anti-drug agency has introduced a Portuguese-style drug policy – considering drug addiction as a chronic diseased to be treated.

Heroin users in the Seychelles have two options:

  • Join a high threshold Methadone Maintenance Programme (MMP), which includes a period of in-patient treatment where they must commit to detoxification
  • Or the low threshold programme, which focuses on harm reduction

Individuals have access to medical and psychosocial support under both programmes.

Patrick Herminie, who had previously attended one of the programmes, has stated “currently, we have over 2000 people registered in one of our programmes and 68% of those are now gainfully employed”.  Each morning he visits one of the country’s mobile methadone clinics, white vans that are manned by drug counsellors and qualified nurses to give the correct dose of methadone to recovering addicts. People line up outside the open windows of the van, ready to show their ID. Their name, the date and time are logged into a spreadsheet on receipt of the information and the correct dose of methadone is distributed to them.

Utilising our patented Biochip Array Technology, our DoA ULTRA panel, available for the Evidence Investigator, offers the most comprehensive drugs of abuse screen across multiple forensic matrices. Detecting up to 20 targets drugs including heroin and other opioids, it has the largest cross-reactivity profile of over 240 analytes. Our excellent assay precision and performance eliminates false reporting, offering CVs of typically <10%. Randox Toxicology produce an accurate drug profile to ensure confidence in results.

To find out more about our Biochip Array Technology and our Evidence Series range of analysers, visit www.randoxtoxicology.com or email info@randoxtoxicology.com

Randox Toxicology Products and Services

BIOCHIP

EVIDENCE

ELISA

MATRICES

Want to know more about Randox?

Contact us or visit our homepage to view more.


Medlab Middle East

Join us for Medlab Middle East 2020!

 

Randox Laboratories will be attending Medlab Middle East form the 3rd February – 6th February 2020. Our innovative diagnostic solutions have been developed with consolidation and economy in mind, providing cost savings whilst using pioneering technology.

Diagnostics is our passion. We are dedicated to developing solutions that not only meet your needs, but that are of the highest quality, the most reliable and the most cost-effective. We look forward to meeting you in the Dubai International Convention & Exhibition Centre at stand Z5.B10.

 

New Products

  • Serology Controls
  • Stroke Biochip
  • Lipoprotein(a)
  • H-FABP in CSA-AKI Testing
  • Acusera Verify
  • Evidence+

Acusera Infectious Disease Serology Controls

Randox Quality Control are pleased to announce the launch of our new Infectious Disease Serology Internal Quality Controls. Our portfolio includes Lyme Disease, ToRCH, EBV, HIV, HAV, HTLV, CMV, VZV and much more.

All samples are provided in a user-friendly, liquid ready-to-use format. This significantly reduces preparation time and the risk of pipetting errors.

There is approximately 1 million people in the USA living with HIV and around 15% of them are unaware they are infected (CDC, March 2019). Furthermore, the Centers for Disease Control and Prevention (CDC) estimate that around 39,000 new HIV infections are reported per year.

The impact of not only HIV but all infectious diseases is getting much greater. Therefore, laboratories now play a much more important role in providing accurate test results. This is a key component in controlling the spread of infections.

Reporting a false positive result has its own obvious implications, however, what about the consequences of reporting a false negative. This can be just as devastating to a person in terms of the treatment they will receive and even personal lifestyle changes for the patient in question.

Randox Stroke Biochip

The Randox Stroke Biochip is a rapid and highly sensitive blood test that will complement and enhance existing CT scanning technology to facilitate accurate classification of stroke patients and improve patient care pathways.

Using Randox revolutionary patented Biochips, the Randox Stroke Biochip provides a unique solution for simultaneous detection of multiple stroke biomarkers from a single sample, facilitating fast and accurate classification of stroke patients in an emergency setting.

Benefits of the Randox Stroke Biochip

> Multiplex biochip for rapid stroke classification in under 30 minutes from a single plasma sample

> Complements and enhances existing CT scanning ensuring fast and accurate diagnosis

> Fast and accurate diagnostic classification between ischaemic and haemorrhagic stroke

> Simple 2 step process from sample entry to results

> Ensures better outcomes guaranteeing timely therapeutic intervention

Lipoprotein(a) [Lp(a)]

 Lipoprotein(a) [Lp(a)] is described as “the most complex and polymorphic of the lipoprotein particles” 1. The biggest challenge that exists surrounding Lp(a) measurement is the heterogeneity of the apo(a) isoforms. Standardisation across calibrators is vital as the repeated KIV-2 units in Lp(a) act as multiple epitopes. A lack of standardisation could result in the underestimation of Lp(a) associated CVD risk 2.

Lp(a) assays that are standardised to the WHO/IFCC reference material, transferring values from mg/dl to nmol/l are more uniformed. The Denka Seiken Lp(a) assay is the most reliable commercially available Lp(a) assay, because 2:

  1. The isoform size variations are reduced as a range of calibrators from separate pools of serum were used which covered a range of Lp(a) concentrations.
  2. The isoform size and concentrations are inversely correlated better matching calibrants with test samples.
  3. Methods based on the Denka Lp(a) assay, calibrated in nmol/l and traceable to the WHO/IFCC reference material produced an acceptable bias compared with the Northwest Lipid Metabolism and Diabetes Research Laboratory (NLMDRKL) gold standard method.

 

HEART UK advocate the widespread clinical utility of Lp(a) to refine the CVD risk assessment. In doing so, HEART UK developed ten statements on Lp(a) (Table 1) utilising the 2016 ACC/AHA Clinical Guideline Recommendation Classification System, to assess the strength of the recommendation and aid in guiding the phrasing of the recommendation 2.

Key Features of the Randox Lp(a) Assay

  • The Randox Lp(a) assay is one of the only methodologies on the market that detects the non-variable part of the Lp(a) molecule and therefore suffers minimal size related bias providing more accurate and consistent results. The Randox Lp(a) kit is standardised to the WHO/IFCC reference material (IFCC SRM 2B) and is closest in terms of agreement to the ELISA reference method.
  • Five-point calibrator with accuracy-based assigned target values, and control are available, accurately reflecting the heterogeneity of the apo(a) isoforms present in the general population and offering a complete testing package.
  • Measuring units are available in nmol/l which is more uniformed and recommended by HEART UK.
  • Immunoturbidimetric method is highly sensitive and specific for the detection of Lp(a) in serum and plasma.
  • Excellent correlation co-efficient of r=0.995 when compared against other commercially available methods.
  • Excellent within run precision of <2.54%.
  • Liquid ready-to-use format for convenience and ease-of-use.
  • Applications available detailing instrument-specific settings for the convenient use of the Randox Lp(a) assay on a wide range of clinical chemistry analysers.

 

References

  1. Marcovina SM, Albers JJ. Lipoprotein (a) measurements for clinical application . Journal of Lipid Research 2019; 57(): 526-537.
  2. Cegla J, Dermot R, Neely G, France M, Ferns G, et al. HEART UK consensus statement on Lipoprotein(a): A call to action. Atherosclerosis 2019; 291(): 62-70.

H-FABP in CSA-AKI Testing

Cardiac surgery-associated acute kidney injury (CSA-AKI) is a well-recognised postoperative complication of cardiac surgery and is the second most common cause of AKI in the ICU, occurring in up to 30% of patients. Higher pre-operative values of H-FABP were associated with a higher risk of developing AKI. Following adjustments of certain patient characteristics, the association of pre-operative H-FABP with the development of AKI remained significant. In fact, the researchers observed that a 1 unit increase in log H-FABP was associated with a 3-fold increase in the odds of developing AKI.

Meet CLIA requirements with accuracy and ease

Acusera Linearity Sets are designed to challenge a larger section of an instruments reportable range and test if a system’s calibration is still valid. Our linearity materials cover a wide range of testing including, CRP, RF, Lipids, Therapeutic Drugs, Esoterics and more. Designed with user convenience in mind, all our linearity sets are supplied in a liquid format, while also presented in varying levels. Our unique combination of analytes enables laboratories to reduce the number of individual products required while ultimately reducing costs and time.

Complimentary, cloud-based data reduction software is supplied with all linearity sets, providing a graphical representation of results for at-a-glance performance assessment.  Access to instantly updated peer group data and automatically generated statistics also helps to speed up data review.

The new Evidence+

The fully automated Evidence+ analyzer is set to truly revolutionize laboratories worldwide. Continuing to provide high standards of quality, efficiency and reliability, the fully automated batch immunoanalyzer simultaneously detects multiple drugs and drug metabolites from a single sample.

The Evidence+ analyzer enables both efficient and cost-effective testing whilst providing accurate and reliable results to larger high throughput laboratories.

What can we offer?

  • Biosciences
  • Quality Control
  • EQA
  • QCMD
  • Qnostics
  • Reagents
  • Evidence Series
  • RX Series
  • Toxicology
vivalytic

Randox Biosciences is part of Randox Laboratories and is dedicated to advancing scientific discovery, drug development and diagnostics. We provide a variety of services and products to numerous industries including clinical laboratories, biopharma and academic research institutes.

Our revolutionary multiplex Biochip Array Technology includes multiplex protein immunoassays and multiplex nucleic acid arrays, and is delivered via the award winning Evidence range of analysers. Biochip Array Technology is a multi-analyte testing platform facilitating the simultaneous quantitative or qualitative detection of a wide range of analytes from a single sample. Biochip provides a unique platform for assessment in a rapid, accurate and easy to use format.

Vivalytic

Vivalytic the newest offering from Randox Biosciences brings innovation to the Molecular Diagnostic industry providing tests for respiratory, genitourinary and hospital acquired infections. The Vivalytic platform is capable of both Hi-Plex and Lo-Plex testing. Nucleic acid extraction, PCR amplification followed by a suite of detection methods are combined in a truly revolutionary, fully automated platform. Manual preparation, cold chain reagents and the use of multiple devices are no longer required making Vivalytic  a unique space-saving, hygienic solution for Molecular Diagnostic testing.

Leading provider of true third-party controls

With over 390 parameters available in our Acusera range, choice and flexibility is guaranteed. Moreover, the availability of truly independent third-party controls coupled with the added advantages of highly accurate target values, excellent stability and unparalleled quality will enhance performance, save valuable time and minimize waste in any laboratory. Our comprehensive range of multi-analyte controls have been uniquely developed with user convenience in mind. By combining more than 100 parameters in a single vial, laboratories can significantly reduce the need for multiple, costly single analyte controls.

Online QC software with real-time peer group statistics

Designed to help you efficiently review QC data from multiple laboratory instruments on one centralized platform, Acusera 24.7 allows quick and easy identification of QC failures and emerging trends.

Unique access to live peer group updates will reduce time and money spent troubleshooting, helping you to instantly discover if an issue is isolated to your lab or a widespread problem. The added benefit of automatically generated statistics including Sigma Scores, Measurement Uncertainty & Total Error as well as fully interactive charts & reports will enable quick and easy performance monitoring.

Book a live demonstration for Acusera 24.7

Meet CLIA requirements with accuracy and ease

Acusera Linearity Sets are designed to challenge a larger section of an instruments reportable range and test if a system’s calibration is still valid. Our linearity materials cover a wide range of testing including, CRP, RF, Lipids, Therapeutic Drugs, Esoterics and more. Designed with user convenience in mind, all our linearity sets are supplied in a liquid format, while also presented in varying levels. Our unique combination of analytes enables laboratories to reduce the number of individual products required while ultimately reducing costs and time.

Complimentary, cloud-based data reduction software is supplied with all linearity sets, providing a graphical representation of results for at-a-glance performance assessment.  Access to instantly updated peer group data and automatically generated statistics also helps to speed up data review.

RIQAS – The World’s Largest International PT scheme

With over 45,000 laboratory participants in more than 133 countries, the Randox International Quality Assessment Scheme (RIQAS) is truly the largest international PT provider in the world. Our comprehensive product offering currently covers over 360 parameters across 33 flexible programmes. Each RIQAS programme contains a unique combination of parameters meaning laboratories can significantly reduce the number of individual programmes required whilst increasing efficiency and reducing costs. Further benefits to a laboratory include accreditation to ISO 17043:2010, frequent reporting, reduced parameter options and access to comprehensive yet user-friendly reports.

QCMD is a world leading External Quality Assessment (EQA) / Proficiency Testing (PT) scheme, dedicated to improving the quality of molecular diagnostic assays used in the detection of infectious diseases.

With an extensive database of over 2000 participants in over 100 countries, QCMD is one of the largest providers of molecular EQA in the field of molecular diagnostics.

Molecular Infectious Disease Controls

Qnostics is a leading manufacturer of Third Party Quality Control solutions for Molecular Infectious Disease testing. Supplying microbiology/virology laboratories, molecular diagnostic assay manufacturers, EQA providers, pharmaceutical and CRO organisations for over a decade.

Designed to meet the demand of today’s molecular diagnostics laboratory and laboratories carrying out Nucleic Acid Testing (NAT), the Qnostics Molecular Infectious Disease range comprises hundreds of characterised viral, bacterial and fungal targets covering a wide range of Transplant Associated Diseases, Respiratory Infections, Blood Borne Viruses, Sexually Transmitted Infections, Gastrointestinal Diseases and Central Nervous System Diseases.

Randox Reagents are internationally recognised as being of the highest quality, offering reliable and rapid results. Our product portfolio consists of 117 clinical chemistry assays, covering a range of testing panels, including: antioxidants, diabetes, cardiology and lipids, specific proteins, therapeutic drug monitoring and veterinary testing.

Randox are continuously striving to improve diagnostic solutions worldwide.  As a result, Randox have produced 29 niche and superior performance assays, including: 5th Generation Bile Acids, Adiponectin, Aldolase, Copper, Cystatin C, D-3-Hydroxybutyrate, G6PDH, H-FABP, Lipoprotein (a), NEFA, HDL Cholesterol, sdLDL Cholesterol, Total Antioxidant Status and Zinc.

Evidence series immunoassay analysers guarantee cost-effective, highly accurate and flexible testing solutions. Having been developed to work with patented Biochip Array Technology, this precision multiplex testing platform allows for the simultaneous quantitative or qualitative detection of a wide range of analytes from a single sample.

This multiplex system delivers an unrivalled increase in patient information, offering a more in-depth diagnostic profile with each patient sample. This further analysis places the focus on the diagnosis, and on improving patient outcomes.

Renowned for quality and reliability, the RX series leads the way with the world’s most extensive dedicated clinical chemistry test menu comprising routine chemistries, specific proteins, lipids, therapeutic drugs, antioxidants, veterinary and diabetes testing. Guaranteeing real cost savings through consolidation of routine and specialised tests onto a single platform, the RX series of analysers delivers excellence in patient care, offering unrivalled precision, accuracy and reliability.

RX misano

The RX misano semi-automated analyser has been developed with the user in mind by incorporating a responsive touch-screen display. The sleek ergonomic design boasts intuitive user-friendly software allowing for test menu personalisation and ease of use. The RX misano is capable of high standard, precise results at a competitive price per test.

RX monaco

The RX monaco is a fully automated solution for low to mid volume clinical chemistry testing offering the ultimate in convenience, performance and confidence. At optimal configuration, the RX monaco performs 170 tests per hour providing cost effective, high quality testing.

RX daytona +

The RX daytona+ is a fully automated, benchtop, clinical chemistry analyser capable of performing high quality testing, with a combined throughput of 450 tests per hour, for accurate results you can trust. The most versatile analyser in its class, the RX daytona+ combines robust hardware and intuitive software with the world leading RX series test menu for unrivalled performance with direct HbA1c testing capabilities.

RX imola

The RX imola is a cost-effective system that delivers consistent high-quality results. Capable of handling the workload of a medium to high throughout laboratory and a combined throughput of 560 tests per hour, the RX imola provides rapid, comprehensive testing on a small footprint analyser with direct HbA1c testing capabilities. The RX imola is a fully automated system with random access and STAT sampling functionality, boosting productivity and saving time when it matters most

RX modena

Capable of performing up to 1,200 tests per hour, with direct HbA1c testing capabilities, the RX modena consolidates all your assay requirements onto one intuitive platform. The RX modena boasts icon based, interactive touch-screen technology adding a modern flair to your laboratory.

Find out more about Direct HbA1c
Book a demonstration of one of our analysers

Randox Toxicology offer the most comprehensive Drugs of Abuse (DoA) test menu across multiple forensic matrices. Our level of expertise in toxicology research and development allows us to adapt quickly to ever changing market influences and develop assays for current and novel drug trends. Excellent assay precision and performance eliminates false reporting, therefore reducing unnecessary confirmatory tests and time lost in the laboratory as a result. Our Biochip Arrays offer CVs typically less than 10%, producing an accurate drug profile to ensure confidence in results.

Want to know more?

Contact us or book a meeting with us





Medica 2019

Join us for MEDICA 2019!

 

 

Randox Laboratories will be attending MEDICA 2019 from the 18th – 22nd November 2019. Our innovative diagnostic solutions have been developed with consolidation and economy in mind, providing cost savings whilst using pioneering technology.

Diagnostics is our passion. We are dedicated to developing solutions that not only meet your needs, but that are of the highest quality, the most reliable and the most cost-effective. We look forward to meeting you in the Messe Düsseldorf, Germany.

New Products

  • Serology Controls
  • Adiponectin
  • Stroke Biochip
  • Evidence+
  • Acusera Verify
  • H-FABP in CSA-AKI Testing

Acusera Infectious Disease Serology Controls

Randox Quality Control are pleased to announce the launch of our new Infectious Disease Serology Internal Quality Controls. Our portfolio includes Lyme Disease, ToRCH, EBV, HIV, HAV, HTLV, CMV, VZV and much more.

All samples are provided in a user-friendly, liquid ready-to-use format. This significantly reduces preparation time and the risk of pipetting errors.

There is approximately 1 million people in the USA living with HIV and around 15% of them are unaware they are infected (CDC, March 2019). Furthermore, the Centers for Disease Control and Prevention (CDC) estimate that around 39,000 new HIV infections are reported per year.

The impact of not only HIV but all infectious diseases is getting much greater. Therefore, laboratories now play a much more important role in providing accurate test results. This is a key component in controlling the spread of infections.

Reporting a false positive result has its own obvious implications, however, what about the consequences of reporting a false negative. This can be just as devastating to a person in terms of the treatment they will receive and even personal lifestyle changes for the patient in question.

Adiponectin

Adiponectin (adipocyte complement-related protein of 30kDa (Acrp30)) is an adipokine (protein hormone) produced and secreted by the adipose tissue, an endocrine organ. Adiponectin acts as a messenger in the communication of adipose tissue and metabolic organs. In doing so, Adiponectin suppresses the production of glucose in the liver through inhibiting the genes involved in glucose production and enhances fatty acid oxidation in skeletal muscle 2. Consequently, Adiponectin is a strong protector against several pathological events in various cells through inhibiting inflammation, suppressing cell death and enhancing cell survival. Adiponectin has been identified as having pleiotropic functions widely associated with anti-atherogenic, anti-diabetic, cardioprotective and anti-inflammatory effects.

Randox Stroke Biochip

The Randox Stroke Biochip is a rapid and highly sensitive blood test that will complement and enhance existing CT scanning technology to facilitate accurate classification of stroke patients and improve patient care pathways.

Using Randox revolutionary patented Biochips, the Randox Stroke Biochip provides a unique solution for simultaneous detection of multiple stroke biomarkers from a single sample, facilitating fast and accurate classification of stroke patients in an emergency setting.

Benefits of the Randox Stroke Biochip

> Multiplex biochip for rapid stroke classification in under 30 minutes from a single plasma sample

> Complements and enhances existing CT scanning ensuring fast and accurate diagnosis

> Fast and accurate diagnostic classification between ischaemic and haemorrhagic stroke

> Simple 2 step process from sample entry to results

> Ensures better outcomes guaranteeing timely therapeutic intervention

The new Evidence+

The fully automated Evidence+ analyzer is set to truly revolutionize laboratories worldwide. Continuing to provide high standards of quality, efficiency and reliability, the fully automated batch immunoanalyzer simultaneously detects multiple drugs and drug metabolites from a single sample.

The Evidence+ analyzer enables both efficient and cost-effective testing whilst providing accurate and reliable results to larger high throughput laboratories.

Meet CLIA requirements with accuracy and ease

Acusera Linearity Sets are designed to challenge a larger section of an instruments reportable range and test if a system’s calibration is still valid. Our linearity materials cover a wide range of testing including, CRP, RF, Lipids, Therapeutic Drugs, Esoterics and more. Designed with user convenience in mind, all our linearity sets are supplied in a liquid format, while also presented in varying levels. Our unique combination of analytes enables laboratories to reduce the number of individual products required while ultimately reducing costs and time.

Complimentary, cloud-based data reduction software is supplied with all linearity sets, providing a graphical representation of results for at-a-glance performance assessment.  Access to instantly updated peer group data and automatically generated statistics also helps to speed up data review.

H-FABP in CSA-AKI Testing

Cardiac surgery-associated acute kidney injury (CSA-AKI) is a well-recognised postoperative complication of cardiac surgery and is the second most common cause of AKI in the ICU, occurring in up to 30% of patients. Higher pre-operative values of H-FABP were associated with a higher risk of developing AKI. Following adjustments of certain patient characteristics, the association of pre-operative H-FABP with the development of AKI remained significant. In fact, the researchers observed that a 1 unit increase in log H-FABP was associated with a 3-fold increase in the odds of developing AKI.

What can we offer?

  • Biosciences
  • Acusera
  • RIQAS
  • Qnostics
  • Reagents
  • RX Series
  • Toxicology
  • Evidence Series
vivalytic

Randox Biosciences is part of Randox Laboratories and is dedicated to advancing scientific discovery, drug development and diagnostics. We provide a variety of services and products to numerous industries including clinical laboratories, biopharma and academic research institutes.

Our revolutionary multiplex Biochip Array Technology includes multiplex protein immunoassays and multiplex nucleic acid arrays, and is delivered via the award winning Evidence range of analysers. Biochip Array Technology is a multi-analyte testing platform facilitating the simultaneous quantitative or qualitative detection of a wide range of analytes from a single sample. Biochip provides a unique platform for assessment in a rapid, accurate and easy to use format.

Vivalytic

Vivalytic the newest offering from Randox Biosciences brings innovation to the Molecular Diagnostic industry providing tests for respiratory, genitourinary and hospital acquired infections. The Vivalytic platform is capable of both Hi-Plex and Lo-Plex testing. Nucleic acid extraction, PCR amplification followed by a suite of detection methods are combined in a truly revolutionary, fully automated platform. Manual preparation, cold chain reagents and the use of multiple devices are no longer required making Vivalytic  a unique space-saving, hygienic solution for Molecular Diagnostic testing.

Leading provider of true third-party controls

With over 390 parameters available in our Acusera range, choice and flexibility is guaranteed. Moreover, the availability of truly independent third-party controls coupled with the added advantages of highly accurate target values, excellent stability and unparalleled quality will enhance performance, save valuable time and minimize waste in any laboratory. Our comprehensive range of multi-analyte controls have been uniquely developed with user convenience in mind. By combining more than 100 parameters in a single vial, laboratories can significantly reduce the need for multiple, costly single analyte controls.

Online QC software with real-time peer group statistics

Designed to help you efficiently review QC data from multiple laboratory instruments on one centralized platform, Acusera 24.7 allows quick and easy identification of QC failures and emerging trends.

Unique access to live peer group updates will reduce time and money spent troubleshooting, helping you to instantly discover if an issue is isolated to your lab or a widespread problem. The added benefit of automatically generated statistics including Sigma Scores, Measurement Uncertainty & Total Error as well as fully interactive charts & reports will enable quick and easy performance monitoring.

Book a live demonstration for Acusera 24.7

Meet CLIA requirements with accuracy and ease

Acusera Linearity Sets are designed to challenge a larger section of an instruments reportable range and test if a system’s calibration is still valid. Our linearity materials cover a wide range of testing including, CRP, RF, Lipids, Therapeutic Drugs, Esoterics and more. Designed with user convenience in mind, all our linearity sets are supplied in a liquid format, while also presented in varying levels. Our unique combination of analytes enables laboratories to reduce the number of individual products required while ultimately reducing costs and time.

Complimentary, cloud-based data reduction software is supplied with all linearity sets, providing a graphical representation of results for at-a-glance performance assessment.  Access to instantly updated peer group data and automatically generated statistics also helps to speed up data review.

RIQAS – The World’s Largest International PT scheme

With over 45,000 laboratory participants in more than 133 countries, the Randox International Quality Assessment Scheme (RIQAS) is truly the largest international PT provider in the world. Our comprehensive product offering currently covers over 360 parameters across 33 flexible programmes. Each RIQAS programme contains a unique combination of parameters meaning laboratories can significantly reduce the number of individual programmes required whilst increasing efficiency and reducing costs. Further benefits to a laboratory include accreditation to ISO 17043:2010, frequent reporting, reduced parameter options and access to comprehensive yet user-friendly reports.

Molecular Infectious Disease Controls

Qnostics is a leading manufacturer of Third Party Quality Control solutions for Molecular Infectious Disease testing. Supplying microbiology/virology laboratories, molecular diagnostic assay manufacturers, EQA providers, pharmaceutical and CRO organisations for over a decade.

Designed to meet the demand of today’s molecular diagnostics laboratory and laboratories carrying out Nucleic Acid Testing (NAT), the Qnostics Molecular Infectious Disease range comprises hundreds of characterised viral, bacterial and fungal targets covering a wide range of Transplant Associated Diseases, Respiratory Infections, Blood Borne Viruses, Sexually Transmitted Infections, Gastrointestinal Diseases and Central Nervous System Diseases.

Randox Reagents are internationally recognised as being of the highest quality, offering reliable and rapid results. Our product portfolio consists of 111 clinical chemistry assays, covering a range of testing panels, including: antioxidants, diabetes, drugs of abuse testing, cardiology and lipids, specific proteins, therapeutic drug monitoring and veterinary testing.

Randox are continuously striving to improve diagnostic solutions worldwide.  As a result, Randox have produced 29 niche and superior performance assays, including: 5th Generation Bile Acids, Adiponectin, Aldolase, Copper, Cystatin C, D-3-Hydroxybutyrate, G6PDH, H-FABP, Lipoprotein (a), NEFA, HDL Cholesterol, sdLDL Cholesterol, Total Antioxidant Status and Zinc.

Renowned for quality and reliability, the RX series leads the way with the world’s most extensive dedicated clinical chemistry test menu comprising routine chemistries, specific proteins, lipids, therapeutic drugs, antioxidants, veterinary and diabetes testing. Guaranteeing real cost savings through consolidation of routine and specialised tests onto a single platform, the RX series of analysers delivers excellence in patient care, offering unrivalled precision, accuracy and reliability.

RX misano

The RX misano semi-automated analyser has been developed with the user in mind by incorporating a responsive touch-screen display. The sleek ergonomic design boasts intuitive user-friendly software allowing for test menu personalisation and ease of use. The RX misano is capable of high standard, precise results at a competitive price per test.

RX monaco

The RX monaco is a fully automated solution for low to mid volume clinical chemistry testing offering the ultimate in convenience, performance and confidence. At optimal configuration, the RX monaco performs 170 tests per hour providing cost effective, high quality testing.

RX daytona +

The RX daytona+ is a fully automated, benchtop, clinical chemistry analyser capable of performing high quality testing, with a combined throughput of 450 tests per hour, for accurate results you can trust. The most versatile analyser in its class, the RX daytona+ combines robust hardware and intuitive software with the world leading RX series test menu for unrivalled performance with direct HbA1c testing capabilities.

RX imola

The RX imola is a cost-effective system that delivers consistent high-quality results. Capable of handling the workload of a medium to high throughout laboratory and a combined throughput of 560 tests per hour, the RX imola provides rapid, comprehensive testing on a small footprint analyser with direct HbA1c testing capabilities. The RX imola is a fully automated system with random access and STAT sampling functionality, boosting productivity and saving time when it matters most

RX modena

Capable of performing up to 1,200 tests per hour, with direct HbA1c testing capabilities, the RX modena consolidates all your assay requirements onto one intuitive platform. The RX modena boasts icon based, interactive touch-screen technology adding a modern flair to your laboratory.

Find out more about Direct HbA1c
Book a demonstration of one of our analysers

Randox Toxicology offer the most comprehensive Drugs of Abuse (DoA) test menu across multiple forensic matrices. Our level of expertise in toxicology research and development allows us to adapt quickly to ever changing market influences and develop assays for current and novel drug trends. Excellent assay precision and performance eliminates false reporting, therefore reducing unnecessary confirmatory tests and time lost in the laboratory as a result. Our Biochip Arrays offer CVs typically less than 10%, producing an accurate drug profile to ensure confidence in results.

Evidence series immunoassay analysers guarantee cost-effective, highly accurate and flexible testing solutions. Having been developed to work with patented Biochip Array Technology, this precision multiplex testing platform allows for the simultaneous quantitative or qualitative detection of a wide range of analytes from a single sample.

This multiplex system delivers an unrivalled increase in patient information, offering a more in-depth diagnostic profile with each patient sample. This further analysis places the focus on the diagnosis, and on improving patient outcomes.

Want to know more?

Contact us or book a meeting with us





Request a meeting
×
Make an Enquiry - RX series
×
Make an Enquiry - Reagents
×
Kit Insert Request - Reagents
  • Signing up to our mailing list is quick and easy. We do not wish to send you any spam or junk email, therefore, you can expect to receive mailshots including new product launches and updates, market trends, attendance at key industry events and much more. Randox Laboratories promise never to sell your data and we will keep all your details, safe and secure. Read more in our Privacy Policy.
×
Kit Insert Request - Reagents
  • Signing up to our mailing list is quick and easy. We do not wish to send you any spam or junk email, therefore, you can expect to receive mailshots including new product launches and updates, market trends, attendance at key industry events and much more. Randox Laboratories promise never to sell your data and we will keep all your details, safe and secure. Read more in our Privacy Policy.
×
Make an Enquiry - Reagents
×
Make an Enquiry - Quality Control
×
Make an Enquiry - RIQAS
×
Make an Enquiry - RIQAS
×
Make an Enquiry - Quality Control
×
Make an Enquiry
  • Signing up to our mailing list is quick and easy. We do not wish to send you any spam or junk email, therefore, you can expect to receive mailshots including new product launches and updates, market trends, attendance at key industry events and much more. Randox Laboratories promise never to sell your data and we will keep all your details, safe and secure. Read more in our Privacy Policy.
×
Make an Enquiry - Biochip
  • This field is for validation purposes and should be left unchanged.
×
Make an Enquiry - Molecular
  • Signing up to our mailing list is quick and easy. We do not wish to send you any spam or junk email, therefore, you can expect to receive mailshots including new product launches and updates, market trends, attendance at key industry events and much more. Randox Laboratories promise never to sell your data and we will keep all your details, safe and secure. Read more in our Privacy Policy.
  • This field is for validation purposes and should be left unchanged.
×
Make an Enquiry - Future Diagnostics
×
Make an Enquiry - RX series (Product)
×
Make an Enquiry - Quality Control
  • Signing up to our mailing list is quick and easy. We do not wish to send you any spam or junk email, therefore, you can expect to receive mailshots including new product launches and updates, market trends, attendance at key industry events and much more. Randox Laboratories promise never to sell your data and we will keep all your details, safe and secure. Read more in our Privacy Policy.
×
Make an Enquiry - RIQAS
  • Signing up to our mailing list is quick and easy. We do not wish to send you any spam or junk email, therefore, you can expect to receive mailshots including new product launches and updates, market trends, attendance at key industry events and much more. Randox Laboratories promise never to sell your data and we will keep all your details, safe and secure. Read more in our Privacy Policy.
×
Make an Enquiry - Reagents
  • Signing up to our mailing list is quick and easy. We do not wish to send you any spam or junk email, therefore, you can expect to receive mailshots including new product launches and updates, market trends, attendance at key industry events and much more. Randox Laboratories promise never to sell your data and we will keep all your details, safe and secure. Read more in our Privacy Policy.
×
Por favor, introduzca sus datos para ver nuestro último seminario
×
Wyślij zapytanie
  • Rejestracja na naszej liście mailowej jest szybka i łatwa. Nie chcemy wysyłać e-maili zawierających spam lub wiadomości, które są automatycznie przekierowywane do kosza. W zawiązku z czym firma Randox deklaruje, że będzie wysyłac tylko informacje na temat nowych produktów,akutalizacji obecnych, trendów rynkowych, wydarzeń branżowych itp. Firma Randox Laboraotries obiecuje, że Państwa dane nie będą nigdzie przekazane, a przechowywanie owych danych będzie się odbywało z zachowaniem największego bezpieczeństwa. Prosimy o przeczytani naszje Polityki Prywatności.
×
Wyślij zapytanie
  • Rejestracja na naszej liście mailowej jest szybka i łatwa. Nie chcemy wysyłać e-maili zawierających spam lub wiadomości, które są automatycznie przekierowywane do kosza. W zawiązku z czym firma Randox deklaruje, że będzie wysyłac tylko informacje na temat nowych produktów,akutalizacji obecnych, trendów rynkowych, wydarzeń branżowych itp. Firma Randox Laboraotries obiecuje, że Państwa dane nie będą nigdzie przekazane, a przechowywanie owych danych będzie się odbywało z zachowaniem największego bezpieczeństwa. Prosimy o przeczytani naszje polityki prywatności.
×
Wyślij zapytanie
  • Rejestracja na naszej liście mailowej jest szybka i łatwa. Nie chcemy wysyłać e-maili zawierających spam lub wiadomości, które są automatycznie przekierowywane do kosza. W zawiązku z czym firma Randox deklaruje, że będzie wysyłac tylko informacje na temat nowych produktów,akutalizacji obecnych, trendów rynkowych, wydarzeń branżowych itp. Firma Randox Laboraotries obiecuje, że Państwa dane nie będą nigdzie przekazane, a przechowywanie owych danych będzie się odbywało z zachowaniem największego bezpieczeństwa. Prosimy o przeczytani naszje polityki prywatności.
×
Wyślij zapytanie
    Rejestracja na naszej liście mailowej jest szybka i łatwa. Nie chcemy wysyłać e-maili zawierających spam lub wiadomości, które są automatycznie przekierowywane do kosza. W zawiązku z czym firma Randox deklaruje, że będzie wysyłac tylko informacje na temat nowych produktów,akutalizacji obecnych, trendów rynkowych, wydarzeń branżowych itp. Firma Randox Laboraotries obiecuje, że Państwa dane nie będą nigdzie przekazane, a przechowywanie owych danych będzie się odbywało z zachowaniem największego bezpieczeństwa. Prosimy o przeczytani naszje polityki prywatności .
×
귀하의 문의 사항 제출
    Signing up to our mailing list is quick and easy. We do not wish to send you any spam or junk email, therefore, you can expect to receive mailshots including new product launches and updates, market trends, attendance at key industry events and much more. Randox Laboratories promise never to sell your data and we will keep all your details, safe and secure. Read more in our Privacy Policy.
×
귀하의 문의 사항 제출
×
귀하의 문의 사항 제출
×
귀하의 문의 사항 제출
×
Downloads
×
Contact

<p>

    Randox Clinical Chemistry Products Join the Randox Laboratories Mailing List * I would like to receive emails with new product releases and updates from Randox Laboratories, market trends, and more. I do not want to receive email marketing from Randox. Signing up to our mailing list is quick and easy. We do not want to send you any spam or junk emails, therefore, you can expect to receive mailshots including new product launches and updates, market trends, attendance at key industry events and much more. Randox Laboratories promises never to sell your data and we will keep all your details, safe and secure. Read more in our Privacy Policy.
</p>

×
Enquire Now - Coronavirus Testing